TY - JOUR
T1 - Therapie der obstruktiven Schlafapnoe mittels Alaxo stent
AU - Freuschle, A.
AU - Heiser, C.
AU - Maurer, J. T.
AU - Hörmann, K.
AU - Stuck, B. A.
N1 - Funding Information:
We acknowledge the support of the IAC and the staff of Teide Observatory for the construction and operation of the COSMOSOMAS experiment. Partial funding was provided by grant AYA 2001-1657 from the Spanish Ministry of Science and Education. We thank M. Wolleben for the online 1.4 GHz maps. We thank E. Chapin for useful comments and for revising the English. Also, we would like to thank the referee for useful comments that allowed us to improve this Letter.
PY - 2013/9
Y1 - 2013/9
N2 - Introduction: Continuous positive airway pressure (CPAP) is currently the gold standard in the treatment of obstructive sleep apnea (OSA). Despite its beneficial effects, however, acceptance and compliance is limited. Among the various alternative treatment options, a nasopharyngeal stent (AlaxoStent) has been introduced to stabilize the upper airway. Controlled trials, however, are currently lacking. Material and methods: We intended to test the clinical effects of a nasopharyngeal stent with a prospective controlled clinical trial. After a 2-week treatment period, one night of polysomnography with and one night without having the stent in place were scheduled. Inclusion criteria were as follows: age between 18 and 75 years, documented obstructive sleep apnea (5/h ≤ Apnea-Hypopnea Index ≤∈40/h), velopharyngeal obstruction, and CPAP intolerance. The main exclusion criteria were a BMI >∈35 kg/m 2 and relevant nasal obstruction. Results: Between January 2011 and August 2012 participation in the trial was offered to patients meeting the above mentioned criteria. Within this time period only 22 patients were willing to test the stent. None of those patients, however, were able to use and tolerate the stent during the planned treatment period of 14 days. Discussion: The AlaxoStent
AB - Introduction: Continuous positive airway pressure (CPAP) is currently the gold standard in the treatment of obstructive sleep apnea (OSA). Despite its beneficial effects, however, acceptance and compliance is limited. Among the various alternative treatment options, a nasopharyngeal stent (AlaxoStent) has been introduced to stabilize the upper airway. Controlled trials, however, are currently lacking. Material and methods: We intended to test the clinical effects of a nasopharyngeal stent with a prospective controlled clinical trial. After a 2-week treatment period, one night of polysomnography with and one night without having the stent in place were scheduled. Inclusion criteria were as follows: age between 18 and 75 years, documented obstructive sleep apnea (5/h ≤ Apnea-Hypopnea Index ≤∈40/h), velopharyngeal obstruction, and CPAP intolerance. The main exclusion criteria were a BMI >∈35 kg/m 2 and relevant nasal obstruction. Results: Between January 2011 and August 2012 participation in the trial was offered to patients meeting the above mentioned criteria. Within this time period only 22 patients were willing to test the stent. None of those patients, however, were able to use and tolerate the stent during the planned treatment period of 14 days. Discussion: The AlaxoStent
KW - Alternatives
KW - Continuous positive airway pressure
KW - Nasopharyngeal stent
KW - Obstructive sleep apnea
KW - Snoring
UR - http://www.scopus.com/inward/record.url?scp=84885468271&partnerID=8YFLogxK
U2 - 10.1007/s11818-013-0614-0
DO - 10.1007/s11818-013-0614-0
M3 - Artikel
AN - SCOPUS:84885468271
SN - 1432-9123
VL - 17
SP - 212
EP - 214
JO - Somnologie
JF - Somnologie
IS - 3
ER -